Latanoprost Stada

Latanoprost, the active ingredient in Latanoprost Stada, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure by increasing uveoscleral outflow and is indicated for the management of primary open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for eye‑care formulations across global markets, including emerging markets and established healthcare systems.

Latanoprost is a prostaglandin analog used to reduce intra‑ocular pressure in glaucoma‑related conditions. - Primary open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible. Common Side Effects: - Eye redness: transient hyperemia of the conjunctiva. - Increased eyelash growth: longer, thicker lashes may appear. - Iris pigmentation: gradual darkening of the iris color. - Eye irritation: burning or stinging sensation after instillation. - Blurred vision: temporary visual disturbance. - Foreign body sensation: feeling of something in the eye. Serious or Rare Side Effects: - Severe allergic reaction: swelling, itching, or rash requiring medical attention. - Uveitis: inflammation of the uveal tract that may impair vision. - Corneal edema: swelling of the cornea leading to visual blur. - Paradoxical intra‑ocular pressure increase: unexpected rise in pressure. - Macular edema: fluid accumulation in the macula affecting central vision.

When prescribing Latanoprost, clinicians should observe the following precautions to ensure safe use. - Monitor intra‑ocular pressure: measure IOP regularly to assess therapeutic response. - Assess for ocular infection: avoid use in eyes with active bacterial or viral infection. - Discontinue contact lens use: patients should remove lenses while using the drops. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk. - Systemic prostaglandin sensitivity: exercise caution in patients with asthma or allergic disorders. - Store at room temperature: keep the bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, affecting efficacy or safety. Major Interactions (Avoid): - Concomitant prostaglandin analogs: may increase risk of ocular irritation and pigment changes. - Non‑steroidal anti‑inflammatory eye drops: can reduce Latanoprost’s IOP‑lowering effect. - Systemic carbonic anhydrase inhibitors: additive pressure‑lowering may cause excessive IOP reduction. Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: combined use may produce additive IOP reduction; monitor pressure. - Corticosteroid eye drops: may counteract the pressure‑lowering effect of Latanoprost. - Anticholinergic agents: potential reduction in aqueous outflow; observe IOP trends.